Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Capital Expenditures: 2009-2025

Historic Capital Expenditures for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $2.1 million.

  • Lifecore Biomedical's Capital Expenditures fell 22.71% to $2.1 million in Q2 2025 from the same period last year, while for May 2025 it was $13.4 million, marking a year-over-year decrease of 27.07%. This contributed to the annual value of $13.4 million for FY2025, which is 27.07% down from last year.
  • Per Lifecore Biomedical's latest filing, its Capital Expenditures stood at $2.1 million for Q2 2025, which was down 61.57% from $5.5 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Capital Expenditures ranged from a high of $13.1 million in Q2 2021 and a low of $2.1 million during Q2 2025.
  • Its 3-year average for Capital Expenditures is $4.6 million, with a median of $4.7 million in 2023.
  • In the last 5 years, Lifecore Biomedical's Capital Expenditures skyrocketed by 185.77% in 2021 and then plummeted by 62.18% in 2024.
  • Quarterly analysis of 5 years shows Lifecore Biomedical's Capital Expenditures stood at $5.4 million in 2021, then dropped by 29.06% to $3.8 million in 2022, then grew by 10.73% to $4.3 million in 2023, then plummeted by 42.74% to $2.4 million in 2024, then dropped by 22.71% to $2.1 million in 2025.
  • Its Capital Expenditures was $2.1 million in Q2 2025, compared to $5.5 million in Q1 2025 and $2.4 million in Q4 2024.